About: Outcome of congenital acute lymphoblastic leukemia treated on the Interfant-99 protocol

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Outcome of congenital acute lymphoblastic leukemia treated on the Interfant-99 protocol Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
Description	Acute lymphoblastic leukemia(ALL) diagnosed in the first month of life (congenital ALL) is very rare. Although congenital ALL is often assumed to be fatal,no studies have been published on outcome except for case reports. The present study reports the outcome of 30 patients with congenital ALL treated with the uniform Interfant-99 protocol, a hybrid regimen combining ALL treatment with elements designed for treatment of acute myeloid leukemia. Congenital ALL was characterized by a higher white blood cell count and a strong trend for higher incidence of ML Lrearrangements compared with older infants.Relapse rate was significantly higher in congenital ALL patiens (2-year cumulative incidence [SE] was 60.0 [9.3] vs 34.2 [2.3],P < .001).Two-year event-free survival and survival of congenital ALL patients treated with this protocol was 20%. The survival of 17% after last follow-up,combined with a toxicity profile comparable with that in older infants,justifies treating congenital ALL with curative intent. Acute lymphoblastic leukemia(ALL) diagnosed in the first month of life (congenital ALL) is very rare. Although congenital ALL is often assumed to be fatal,no studies have been published on outcome except for case reports. The present study reports the outcome of 30 patients with congenital ALL treated with the uniform Interfant-99 protocol, a hybrid regimen combining ALL treatment with elements designed for treatment of acute myeloid leukemia. Congenital ALL was characterized by a higher white blood cell count and a strong trend for higher incidence of ML Lrearrangements compared with older infants.Relapse rate was significantly higher in congenital ALL patiens (2-year cumulative incidence [SE] was 60.0 [9.3] vs 34.2 [2.3],P < .001).Two-year event-free survival and survival of congenital ALL patients treated with this protocol was 20%. The survival of 17% after last follow-up,combined with a toxicity profile comparable with that in older infants,justifies treating congenital ALL with curative intent. (en)
Title	Outcome of congenital acute lymphoblastic leukemia treated on the Interfant-99 protocol Outcome of congenital acute lymphoblastic leukemia treated on the Interfant-99 protocol (en)
skos:prefLabel	Outcome of congenital acute lymphoblastic leukemia treated on the Interfant-99 protocol Outcome of congenital acute lymphoblastic leukemia treated on the Interfant-99 protocol (en)
skos:notation	RIV/00216208:11130/09:5345!RIV10-MSM-11130___
http://linked.open...avai/riv/aktivita	Z
http://linked.open...avai/riv/aktivity	Z(MSM0021620813)
http://linked.open...iv/cisloPeriodika	18
http://linked.open...vai/riv/dodaniDat	2010
http://linked.open...aciTvurceVysledku	Starý, Jan
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Univerzita Karlova v Praze / 2. lékařská fakulta
http://linked.open...dnocenehoVysledku	332353
http://linked.open...ai/riv/idVysledku	RIV/00216208:11130/09:5345
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	oncology-group; prognostic-factors; infants; experience; therapy; trial (en)
http://linked.open.../riv/klicoveSlovo	trial prognostic-factors experience therapy infants oncology-group
http://linked.open...odStatuVydavatele	US - Spojené státy americké
http://linked.open...ontrolniKodProRIV	[FDF692176F5F]
http://linked.open...i/riv/nazevZdroje	Blood
http://linked.open...in/vavai/riv/obor	FD
http://linked.open...ichTvurcuVysledku	1 (xsd:int)
http://linked.open...cetTvurcuVysledku	18 (xsd:int)
http://linked.open...UplatneniVysledku	2009
http://linked.open...v/svazekPeriodika	114
http://linked.open...iv/tvurceVysledku	Campbell, M. Pieters, R. Starý, Jan Rubnitz, J. E Biondi, A. Janka, G. Szczepanski, T. De Lorenzo, P. Valsecchi, MG Vora, A. van der Linden, MH Moricke, A. Felice, M. Ferster, A. Hann, I. Hovi, L. Leblanc, T. M. Silverman, LB
http://linked.open...ain/vavai/riv/wos	000271268100010
http://linked.open...n/vavai/riv/zamer	The Molecular Basis of Childhood Malignancies and Therapeutic Applications
issn	0006-4971
number of pages	5 (xsd:int)
http://localhost/t...ganizacniJednotka	11130

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 110 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software